An FDA staff analysis says NitroMed's heart-failure drug BiDil
significantly reduced deaths and hospitalizations among blacks in a
clinical study, and it should be indicated for treatment of black
patients. The staff report was released in advance of today's FDA
advisory panel meeting to decide if BiDil should become the
first drug approved for
treatment of a specific racial group.

Full Story:

Related Summaries